Thiopurine Methyltransferase Gene Polymorphisms in Chinese Patients with Inflammatory Bowel Disease

被引:46
作者
Cao, Qian
Zhu, Qin [2 ]
Shang, Yan
Gao, Min
Si, Jianmin [1 ]
机构
[1] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp,Gastroenterol Unit, Sir Run Run Shaw Inst Clin Med,Dept Gastroenterol, Hangzhou 310016, Zhejiang, Peoples R China
[2] Zhejiang Hosp, Dept Gastroenterol, Hangzhou, Zhejiang, Peoples R China
关键词
Thiopurine methyltransferase; Polymorphisms; Inflammatory bowel disease; ACUTE LYMPHOBLASTIC-LEUKEMIA; S-METHYLTRANSFERASE; AZATHIOPRINE THERAPY; DRUG-INTERACTION; PHARMACOGENETICS; 6-MERCAPTOPURINE; ALLELES; POPULATION; VARIANTS; IDENTIFICATION;
D O I
10.1159/000205268
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Background: The thiopurine drugs azathioprine and 6-mercaptopurine are well established in the treatment of inflammatory bowel disease (IBD). However, great interpatient variability exists in the efficacy and toxicity of the drugs, and this results from thiopurine methyltransferase (TPMT) gene polymorphisms. The aim of this study was to identify the TPMT gene polymorphisms in Chinese IBD patients and to study the relationship between TPMT status and thiopurine-related toxicity in these patients. Materials and Methods: A total of 189 IBD patients, 87 with Crohn's disease and 102 with ulcerative colitis, and 273 healthy controls were enrolled. All subjects were from the Han Chinese ethnic group. Polymorphisms in TPMT*2, *3A, *3B and *3C were analyzed using allele-specific polymerase chain reaction and polymerase chain reaction-restriction fragment length polymorphism. Direct sequencing was used to confirm the mutation results. Exons of the TPMT gene from patients who suffered from azathioprine-induced toxicity were amplified and sequenced to detect TPMT mutations. Results: No TPMT*2, *3A or *3B mutant alleles were detected. The allele frequency of TPMT*3C in the IBD group was 1.59%, which was similar to that of the healthy control group (1.59 vs. 1.47%, p = 1.000). Forty-three patients were treated with azathioprine therapy, 4 experienced myelotoxicity, and 1 experienced hepatotoxicity, so the incidence of drug toxicity was 11.7% (5/43). No TPMT*2, *3A, *3B or *3C polymorphisms were detected in these 5 patients. After directly sequencing the exons of the TPMT gene in these 5 patients, a synonymous single-nucleotide polymorphism (TPMT*1S), which does not alter the encoded amino acid, was found in 3 patients. Conclusion: TPMT*3C seemed to be a unique variant allele in this Han Chinese population. The overall frequencies of variant TPMT alleles in this population were lower than those in Caucasians, but thiopurine toxicity in Han Chinese IBD patients is not low. Factors other than TPMT polymorphisms may be responsible for the development of toxicity. Copyright (c) 2009 S. Karger AG, Basel
引用
收藏
页码:58 / 63
页数:6
相关论文
共 34 条
[1]
Thiopurine methyltransferase alleles in British and Ghanaian populations [J].
Ameyaw, MM ;
Collie-Duguid, ESR ;
Powrie, RH ;
Ofori-Adjei, D ;
McLeod, HL .
HUMAN MOLECULAR GENETICS, 1999, 8 (02) :367-370
[2]
Cao Q, 2005, CHINESE MED J-PEKING, V118, P747
[3]
The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations [J].
Collie-Duguid, ESR ;
Pritchard, SC ;
Powrie, RH ;
Sludden, J ;
Collier, DA ;
Li, T ;
McLeod, HL .
PHARMACOGENETICS, 1999, 9 (01) :37-42
[4]
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy [J].
Colombel, JF ;
Ferrari, N ;
Debuysere, H ;
Marteau, P ;
Gendre, JP ;
Bonaz, B ;
Soulé, JC ;
Modgliani, R ;
Touze, Y ;
Catala, P ;
Libersa, C ;
Broly, F .
GASTROENTEROLOGY, 2000, 118 (06) :1025-1030
[5]
Thiopurine Methyltransferase Activity Influences Clinical Response to Azathioprine in Inflammatory Bowel Disease [J].
Cuffari, Carmen ;
Dassopoulos, Themistocles ;
Turnbough, Lisa ;
Thompson, Richard E. ;
Bayless, Theodore M. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (05) :410-417
[6]
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease [J].
Dubinsky, MC ;
Lamothe, S ;
Yang, HY ;
Targan, SR ;
Sinnett, D ;
Théorêt, Y ;
Seidman, EG .
GASTROENTEROLOGY, 2000, 118 (04) :705-713
[7]
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease [J].
Dubinsky, MC ;
Yang, HY ;
Hassard, PV ;
Seidman, EG ;
Kam, LY ;
Abreu, MT ;
Targan, SR ;
Vasiliauskas, EA .
GASTROENTEROLOGY, 2002, 122 (04) :904-915
[8]
The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review [J].
Fraser, AG ;
Orchard, TR ;
Jewell, DP .
GUT, 2002, 50 (04) :485-489
[9]
Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease [J].
Gearry, RB ;
Barclay, ML ;
Burt, MJ ;
Collett, JA ;
Chapman, BA .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2004, 13 (08) :563-567
[10]
Pyrosequencing of TPMT Alleles in a general Swedish population and in patients with inflammatory bowel disease [J].
Haglund, S ;
Lindqvist, M ;
Almer, S ;
Peterson, C ;
Taipalensuu, J .
CLINICAL CHEMISTRY, 2004, 50 (02) :288-295